ALZN · Alzamend Neuro, Inc. · Debt
$1.30
-0.01 (-0.76%)
At close · Nov 12
Return incl. dividend (before tax)
Going-concern doubt
— flagged Sep 10, 2026
Substantial doubt about the company's ability to continue as a going concern.
“These factors create substantial doubt about our ability to continue as a going concern for at least one year after the date that our condensed financial statements are issued.”View the 10-Q filed Sep 10, 2026
Market Cap
$6.27M
Shares
4.83M
Volume · Nov 12
23.72K
Avg daily vol (3M)
81.99K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Read debt and covenant terms in your AI or your code through MCP and the API →Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current portion of notes payable | 2024-04-30 | USD 300,714 | 10-K filed 2025-07-22 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.